Summary of multivariate analysis results according to CBU genotype
| Analyzed cohort . | Outcomes . | SNP . | HR . | 95% CI . | P . | |
|---|---|---|---|---|---|---|
| < . | > . | |||||
| Recipients with available CBU samples, n = 696 | Neutrophil engraftment | CTLA4 genotype AA | Reference group | .08 | ||
| CTLA4 genotype AG | 0.85 | 0.69 | 1.05 | .14 | ||
| CTLA4 genotype GG | 1.33 | 1.04 | 1.70 | .02 | ||
| NRM | CTLA4 genotype AA | Reference group | .02 | |||
| CTLA4 genotype AG | 0.68 | 0.47 | 0.98 | .04 | ||
| CTLA4 genotype GG | 1.50 | 1.11 | 2.03 | <.01 | ||
| OS | CTLA4 genotype AA | Reference group | .09 | |||
| CTLA4 genotype AG | 1.19 | 0.91 | 1.56 | .21 | ||
| CTLA4 genotype GG | 1.41 | 1.04 | 1.90 | .02 | ||
| Relapse | CTLA4 genotype AA | Reference group | .07 | |||
| CTLA4 genotype AG | 1.35 | 0.83 | 2.17 | .22 | ||
| CTLA4 genotype GG | 1.19 | 0.82 | 1.27 | .35 | ||
| DFS | CTLA4 genotype AA | Reference group | .06 | |||
| CTLA4 genotype AG | 1.21 | 0.93 | 1.57 | .15 | ||
| CTLA4 genotype GG | 1.41 | 1.06 | 1.88 | .02 | ||
| Recipients with available CBU samples and HR-HLA data (n = 305)* | Neutrophil engraftment | CTLA4 genotype AA | Reference group | .16 | ||
| CTLA4 genotype AG | 0.74 | 0.54 | 1.01 | .07 | ||
| CTLA4 genotype GG | 1.33 | 0.92 | 1.92 | .13 | ||
| NRM | CTLA4 genotype AA | Reference group | .05 | |||
| CTLA4 genotype AG | 0.68 | 0.38 | 1.2 | .18 | ||
| CTLA4 genotype GG | 1.85 | 1.14 | 3.00 | .01 | ||
| OS | CTLA4 genotype AA | Reference group | .07 | |||
| CTLA4 genotype AG | 1.05 | 0.70 | 1.59 | .81 | ||
| CTLA4 genotype GG | 1.54 | 0.99 | 2.41 | .06 | ||
| Relapse | CTLA4 genotype AA | Reference group | .25 | |||
| CTLA4 genotype AG | 1.49 | 0.75 | 2.94 | .66 | ||
| CTLA4 genotype GG | 1.12 | 0.65 | 1.96 | .25 | ||
| DFS | CTLA4 genotype AA | Reference group | .17 | |||
| CTLA4 genotype AG | 1.16 | 0.78 | 1.73 | .46 | ||
| CTLA4 genotype GG | 1.49 | 0.96 | 2.30 | .07 | ||
| Analyzed cohort . | Outcomes . | SNP . | HR . | 95% CI . | P . | |
|---|---|---|---|---|---|---|
| < . | > . | |||||
| Recipients with available CBU samples, n = 696 | Neutrophil engraftment | CTLA4 genotype AA | Reference group | .08 | ||
| CTLA4 genotype AG | 0.85 | 0.69 | 1.05 | .14 | ||
| CTLA4 genotype GG | 1.33 | 1.04 | 1.70 | .02 | ||
| NRM | CTLA4 genotype AA | Reference group | .02 | |||
| CTLA4 genotype AG | 0.68 | 0.47 | 0.98 | .04 | ||
| CTLA4 genotype GG | 1.50 | 1.11 | 2.03 | <.01 | ||
| OS | CTLA4 genotype AA | Reference group | .09 | |||
| CTLA4 genotype AG | 1.19 | 0.91 | 1.56 | .21 | ||
| CTLA4 genotype GG | 1.41 | 1.04 | 1.90 | .02 | ||
| Relapse | CTLA4 genotype AA | Reference group | .07 | |||
| CTLA4 genotype AG | 1.35 | 0.83 | 2.17 | .22 | ||
| CTLA4 genotype GG | 1.19 | 0.82 | 1.27 | .35 | ||
| DFS | CTLA4 genotype AA | Reference group | .06 | |||
| CTLA4 genotype AG | 1.21 | 0.93 | 1.57 | .15 | ||
| CTLA4 genotype GG | 1.41 | 1.06 | 1.88 | .02 | ||
| Recipients with available CBU samples and HR-HLA data (n = 305)* | Neutrophil engraftment | CTLA4 genotype AA | Reference group | .16 | ||
| CTLA4 genotype AG | 0.74 | 0.54 | 1.01 | .07 | ||
| CTLA4 genotype GG | 1.33 | 0.92 | 1.92 | .13 | ||
| NRM | CTLA4 genotype AA | Reference group | .05 | |||
| CTLA4 genotype AG | 0.68 | 0.38 | 1.2 | .18 | ||
| CTLA4 genotype GG | 1.85 | 1.14 | 3.00 | .01 | ||
| OS | CTLA4 genotype AA | Reference group | .07 | |||
| CTLA4 genotype AG | 1.05 | 0.70 | 1.59 | .81 | ||
| CTLA4 genotype GG | 1.54 | 0.99 | 2.41 | .06 | ||
| Relapse | CTLA4 genotype AA | Reference group | .25 | |||
| CTLA4 genotype AG | 1.49 | 0.75 | 2.94 | .66 | ||
| CTLA4 genotype GG | 1.12 | 0.65 | 1.96 | .25 | ||
| DFS | CTLA4 genotype AA | Reference group | .17 | |||
| CTLA4 genotype AG | 1.16 | 0.78 | 1.73 | .46 | ||
| CTLA4 genotype GG | 1.49 | 0.96 | 2.30 | .07 | ||
Abbreviations are explained in Table 2.
This cohort is a subset of recipients with available CBU (n = 696).